Match!
Kimberly M Lau
University of California, San Diego
OncologyBlinatumomabPegaspargaseAnesthesiaMedicine
4Publications
0Citations
What is this?
Publications 4
Newest
#1Kimberly M Lau (UCSD: University of California, San Diego)
#2Ila M. Saunders (UM: University of Montana)H-Index: 4
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 10
view all 3 authors...
IntroductionBlinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE) antibody that simultaneously binds CD19 on the surface of B-cells and CD3 on the surface of T-cells, resulting in tumor cell ...
Source
#1Kimberly M Lau (UCSD: University of California, San Diego)
#2Ila M. Saunders (UM: University of Montana)H-Index: 4
Last. Linda Barnachea (UCSD: University of California, San Diego)H-Index: 2
view all 4 authors...
IntroductionHead and neck cancers (HNC) are a complex and heterogeneous group of cancers, often necessitating a multidisciplinary approach across the care continuum. Oncology pharmacists are unique...
Source
#1Kimberly M Lau (UCSD: University of California, San Diego)
#2Ila M. Saunders (UM: University of Montana)H-Index: 4
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 10
view all 3 authors...
Pegaspargase, a long acting formulation of L-asparaginase, is an asparagine specific enzyme that selectively kills leukemic cells by depleting plasma asparagine. Pegaspargase is FDA approved for the first-line treatment of adult acute lymphoblastic leukemia and is a critical component of numerous multi-chemotherapeutic regimens. Pegaspargase is associated with well-described toxicities including hypersensitivity reactions, hepatotoxicity, and thrombosis. However, hypertriglyceridemia is a much r...
Source
Background: Restricting oncology and hematology medications to outpatient infusion centers may be considered when infrequent administration is required, a low risk of serious adverse effects exists, or when prompt amelioration of a condition is not expected. At the University of California, San Diego (UCSD), we created a new formulary status for medications designated "formulary, outpatient-restricted use only." This designation could optimize payer reimbursement, as well as improve patient comf...
1